What is the 13F Pro Quality Score for OKUR?

13F Pro ranks OnKure Therapeutics, Inc. (OKUR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OKUR's current score at https://13fpro.ai/research/OKUR (free sign-up required for the full ranking).

Which hedge funds own the most OKUR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OKUR include RA CAPITAL MANAGEMENT, L.P., ACORN CAPITAL ADVISORS,, StepStone Group. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/OKUR as soon as new 13F filings post.

Where does 13F Pro source OKUR data?

All OnKure Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. OnKure Therapeutics, Inc. files with the SEC under CIK 1637715. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OKUR in?

OnKure Therapeutics, Inc. (OKUR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OKUR research updated on 13F Pro?

OKUR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

OnKure Therapeutics, Inc.(OKUR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1637715 OKUR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

OKUR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for OnKure Therapeutics, Inc. (OKUR), a Healthcare sector company. OKUR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), OnKure Therapeutics, Inc. reports net income of $-15.2M, free cash flow of $-12.9M. Top institutional holders of OKUR by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., ACORN CAPITAL ADVISORS,, StepStone Group, based on the most recent SEC filings. OKUR trades on the Nasdaq exchange and files with the SEC under CIK 1637715. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OKUR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OnKure Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-15.2M

Free Cash Flow

Q1 2026

$-12.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 —FY23 —FY24 $0.00FY25 —

Net Income

-13.0% YoY

$-59.5MFY 2025

FY22 $-52.0MFY23 $-35.3MFY24 $-52.7MFY25 $-59.5M

Operating Income

-15.7% YoY

$-63.0MFY 2025

FY22 $-53.8MFY23 $-36.9MFY24 $-54.4MFY25 $-63.0M

EPS (Diluted)

+71.2% YoY

$-4.40FY 2025

FY22 $-2.12FY23 $-124.41FY24 $-15.28FY25 $-4.40

Total Assets

-45.9% YoY

$62.1MFY 2025

FY22 $108.2MFY23 $107.4MFY24 $114.9MFY25 $62.1M

Op. Cash Flow

-1.4% YoY

$-51.8MFY 2025

FY22 $-47.4MFY23 $-34.5MFY24 $-51.1MFY25 $-51.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	$0.00	—	—	—	—
Net Income	$-59.5M -13.0%	$-52.7M -49.2%	$-35.3M +32.0%	$-52.0M -30.6%	$-39.8M -104.3%	$-19.5M
Operating Income	$-63.0M -15.7%	$-54.4M -47.3%	$-36.9M +31.4%	$-53.8M -35.2%	$-39.8M -103.7%	$-19.6M
EPS (Diluted)	$-4.40 +71.2%	$-15.28 +87.7%	$-124.41 -5768.4%	$-2.12 +3.2%	$-2.19 +77.2%	$-9.60
Total Assets	$62.1M -45.9%	$114.9M +7.0%	$107.4M -0.7%	$108.2M -29.8%	$154.0M +178.9%	$55.2M
Operating Cash Flow	$-51.8M -1.4%	$-51.1M -48.0%	$-34.5M +27.1%	$-47.4M -24.7%	$-38.0M -104.9%	$-18.5M

AI Insight: OKUR Financial Trends

OnKure swung to equity raising in Q1 2026 after six quarters of steady cash burn reduction, but operating losses remain entrenched.

• Operating cash burn improved from $21M in Q4 2024 to $12M–$13M run-rate through Q4 2025, a 40% reduction.

• Operating income losses narrowed from $34M in Q4 2024 to $14M–$16M in Q1–Q4 2025, signaling improving cost discipline.

• Equity surged to $184M in Q1 2026 from $56M in Q4 2025, indicating significant capital raise to extend runway.

⚠ Operating losses remain persistent with no clear path to profitability; no revenue reported across all periods.

⚠ Operating cash burn upticked to $13M in Q1 2026 vs. $12M in Q4 2025—first deterioration in six quarters.

AI Insight: OKUR Ratio Trends

OnKure's profitability metrics deteriorated sharply through 2025 before stabilizing in Q1 2026, but remain deeply negative.

• ROE plummeted from -20.0% in Q3 2024 to -96.1% in Q4 2025, then recovered to -32.9% in Q1 2026.

• ROA and ROIC followed similar destructive pattern: ROA fell to -87.0% in Q4 2025; Q1 2026 shows marginal recovery to -30.5% and -33.9%.

• TTM return metrics remain severely negative: ROE -31.9%, ROA -29.6%, ROIC -33.4% as of Q1 2026.

⚠ Q1 2026 stabilization may signal operational bottom, but all trailing returns remain deeply underwater — sustainability unclear.

⚠ Absence of operating margin, NPM, and D/E data limits visibility into underlying cost structure and capital adequacy.

Get alerted when OKUR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OnKure Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OKUR

RA CAPITAL MANAGEMENT, L.P.
$16.6M3,998,333 sh
ACORN CAPITAL ADVISORS, LLC
$11.8M2,839,674 sh
StepStone Group LP
$11.0M2,660,612 sh
ADAR1 Capital Management, LLC
$10.1M2,434,941 sh
Prosight Management, LP
$8.9M2,154,381 sh
BVF INC/IL
$8.2M1,978,972 sh
Vivo Capital, LLC
$8.0M1,927,710 sh
Vestal Point Capital, LP
$7.6M1,839,819 sh
Foresite Capital Management VI LLC
$6.0M1,445,783 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$5.0M1,204,819 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$16.6M	3,998,333
ACORN CAPITAL ADVISORS, LLC	$11.8M	2,839,674
StepStone Group LP	$11.0M	2,660,612
ADAR1 Capital Management, LLC	$10.1M	2,434,941
Prosight Management, LP	$8.9M	2,154,381
BVF INC/IL	$8.2M	1,978,972
Vivo Capital, LLC	$8.0M	1,927,710
Vestal Point Capital, LP	$7.6M	1,839,819
Foresite Capital Management VI LLC	$6.0M	1,445,783
ADAGE CAPITAL PARTNERS GP, L.L.C.	$5.0M	1,204,819

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OKUR on your watchlist

Track score changes the day OnKure Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OKUR a good stock to buy?

13F Pro's AI-powered analysis of OnKure Therapeutics, Inc. (OKUR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OKUR are available on the OKUR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OKUR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OKUR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OnKure Therapeutics, Inc.'s investment landscape.